Adoptive Immunotherapy for Relapsed Leukemia Following Allogeneic Bone Marrow Transplantation

References

• Barnes D., Loutit J. Treatment of murine leukaemia with X-rays and homologous bone marrow. Br. J. Haematol. 1957; 3: 241
   PubMed Web of Science ®Google Scholar
• Truitt R. L., Le Fever A. V., Shih C. C. Y., Jeske J. M., Martin T. M. Graft-vs-leukemia effect. Graft vs. host disease: immunology, pathophysiology, S. J. Burakoff, H. J. Deeg, J. Ferrara, K. Atkinson. Marcel Dekker, New York 1990; 177–204
   Google Scholar
• Sykes M., Harty M., Szot G., Pearson D. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 1994; 83: 2560
   PubMed Web of Science ®Google Scholar
• Slavin S., Weiss L., Morecki S., Weigenberg M. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol. Immunother. 1981; 11: 155
   Web of Science ®Google Scholar
• Mathe G., Amiel J., Schwarzenberg L., Cattan A., Schneider M. Adoptive immunotherapy of acute leukemia: Experimental and clinical results. Cancer Res. 1965; 25: 1525
   PubMed Web of Science ®Google Scholar
• Higano C., Brixey M., Bryant E., Durnam D., Doney K., Sullivan K., Singer J. Durable complete remission of acute non-lymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation 1990; 50: 175
   PubMed Web of Science ®Google Scholar
• Odom L., August C., Githens J., Humbert J., Morse H., Peakman D., Sharma B., Rusnak S., Johnson F. Remission of relapsed leukaemia during a graft-versus-host reaction. A “graft-versus-leukaemia reaction” in man?. Lancet 1978; 2: 537
   PubMed Web of Science ®Google Scholar
• Gale R., Champlin R. How does bone-marrow transplantation cure leukaemia?. Lancet 1984; 2: 28
   PubMed Web of Science ®Google Scholar
• Weiden P., Flournoy N., Donnall Thomas E., Prentice R., Fefer A., Buckner C., Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 1979; 300: 1068
   PubMed Web of Science ®Google Scholar
• Horowitz M., Gale R., Sondel P., Goldman J., Dersey J., Kolb H., Rimm A., Ringden O., Rozman C., Speck B., Truitt R., Zwaan F., Bortin M. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555
   PubMed Web of Science ®Google Scholar
• Sullivan K., Weiden P., Storb R., Witherspoon R., Fefer A., Fisher L., Buckner C., Anasetti C., Appelbaum F., Badger C., Beatty P., Bensinger W., Berenson R., Bigelow C., Cheever M., Clift R., Deeg H., Doney K., Greenberg P., Hansen J., Hill R., Loughran T., Martin P., Neiman P., Peterson F., Sanders J., Singer J., Stewart P., Thomas E. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989; 73: 1720
   PubMed Web of Science ®Google Scholar
• Goldman J., Gale R., Horowitz M., Biggs J., Champlin R., Gluckman E., Hoffmann R., Jacobsen S., Marmont A., McGlave P., Messner H., Rimm A., Rozman C., Speck B., Tura S., Weiner R., Bortin M. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Ann. Int. Med. 1988; 108: 806
   PubMed Web of Science ®Google Scholar
• Apperley J., Mauro F., Goldman J., Gregory W., Arthur C., Hows J., Arcese W., Papa G., Mandelli F., Wardle D., Gravett P., Franklin I., Bandini G., Ricci P., Tura S., Iacone A., Torlontano G., Heit W., Champlin R., Gale R. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br. J. Haematol. 1988; 69: 239
   PubMed Web of Science ®Google Scholar
• Marmont A., Horowitz M., Gale R., Sobocinski K., Ash R., van Bekkum D., Champlin R., Dicke K., Goldman J., Good R., Herzig R., Hong R., Masaoka T., Rimm A., Ringden O., Speck B., Weiner R., Bortin M. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991; 78: 2120
   PubMed Web of Science ®Google Scholar
• Maraninchi D., Blaise D., Rio B., Leblond V., Dreyfus F., Gluckman E., Guyotat D., Pico J., Michallet M., Ifrah N., Bordigoni A. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987; 2: 175
   PubMed Web of Science ®Google Scholar
• Radich J., Sanders J., Buckner C., Martin P., Petersen F., Bensinger W., McDonald G., Mori M., Schoch G., Hansen J. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J. Clin. Oncol. 1993; 11: 304
   PubMed Web of Science ®Google Scholar
• Mrsic M., Horowitz M., Atkinson K., Biggs J., Champlin R., Ehninger G., Gajewski J., Gale R., Herzig R., Prentice H., Rozman C., Sobocinski K., Speck B., Bortin M. Second HA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9: 269
   PubMed Web of Science ®Google Scholar
• Arcese W., Goldman J., D'Arcangelo E., Schattenberg A., Nardi A., Apperley J., Frassoni F., Aversa F., Prentice H., Ljungman P., Ferrant A., Marosi C., Sayer H., Niederwieser D., Arnold R., Bandini G., Carreras E., Parker A., Frappaz D., Mandelli F., Gratwohl A. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood 1993; 82: 3211
   PubMed Web of Science ®Google Scholar
• Kolb H., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462
   PubMed Web of Science ®Google Scholar
• Bar B., Schattenberg A., Mensink E., Geurts Van Kessel A., Smetsers T., Knops G., Linders E., De Witte T. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J. Clin. Oncol. 1993; 11: 513
   PubMed Web of Science ®Google Scholar
• Cullis J., Jiang Y., Schwarer A., Hughers T., Barrett A., Goldman J. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992; 79: 1379
   PubMed Web of Science ®Google Scholar
• Drobyski W., Keever C., Roth M., Koethe S., Hanson G., McFadden P., Gottschall J., Ash R., van Tuinen P., Horowitz M., Flomenberg N. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993; 82: 2310
   PubMed Web of Science ®Google Scholar
• Helg C., Roux E., Beris P., Cabrol C., Wacker P., Darbellay R., Wyss M., Jeannet M., Chapuis B., Roosnek E. Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 1993; 12: 125
   PubMed Web of Science ®Google Scholar
• Hertenstein B., Wiesneth M., Novotny J., Bunjes D., Stefanic M., Heinze B., Hubner G., Heimpel H., Arnold R. Interferon-α and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplant 1993; 56: 1114
   PubMed Web of Science ®Google Scholar
• Porter D., Roth M., McGarigle C., Ferrara J., Antin J. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N. Engl. J. Med. 1994; 330: 100
   PubMed Web of Science ®Google Scholar
• Kolb H., Mittermuller J., Hertenstein H., Schumm M., Holler E., de Witte T., Gunther W., Ljungman P., Goldman J. Adoptive immunotherapy in human and canine chimeras-the role of Interferon alfa. Sem. Hematol 1993; 30: 37
   PubMed Web of Science ®Google Scholar
• Szer J., Grigg A., Phillipos G., Sheridan W. Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transplant 1993; 11: 109
   PubMed Web of Science ®Google Scholar
• van Rhee F., Cullis J., Feng L., Cross N., Goldman J. Donor leukocyte transfusions (DLT) for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant. Blood 1993; 82(supp. 1)416
   Google Scholar
• Roth M., Antin J., Bingham E., Ginsberg D. Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia. Blood 1989; 74: 882
   PubMed Web of Science ®Google Scholar
• Nimer S., Giorgi J., Gajewski J., Ku N., Schiller G., Lee K., Territo M., Ho W., Feig S., Selch M., Isacescu V., Reichert T., Champlin R. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. Transplant 1994; 57: 82
   PubMed Web of Science ®Google Scholar
• Kolb H., de Witte T., Mittermuller J., Hertenstein B., Goldman J., Ljungman P., Versonck L., Holler E., Thalmaier K., Bartram C. Graft-versus-leukemia effect of donor buffy coat transfusions on recurrent leukemia after marrow transplantation. Blood 1993; 82(suppl)840
   Google Scholar
• Sullivan K., Storb R., Buckner D., Fefer A., Fisher L., Weiden P., Witherspoon R., Appelbaum F., Banaji M., Hansen J., Martin P., Sanders J., Singer J., Thomas E. D. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N. Engl. J. Med. 1989; 320: 828
   PubMed Web of Science ®Google Scholar
• Antin J., Ferrara J. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964
   PubMed Web of Science ®Google Scholar
• Johnson B., Drobyski W., Truitt R. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an anti-leukemia reaction without graft-versus-host disease. Bone Marrow Transplant 1993; 11: 329
   PubMed Web of Science ®Google Scholar
• Weiden P., Storb R., Tsoi M., Graham T., Lerner K., Thomas E. Infusion of donor lymphocytes into stable canine radiation chimeras: Implications for mechanism of transplantation tolerance. J. Immunol. 1978; 116: 1212
   Web of Science ®Google Scholar
• Anderson K., Weinstein H. Transfusion-associated graft-versus-host disease. N. Engl. J. Med. 1990; 323: 315
   PubMed Web of Science ®Google Scholar
• Frassoni F., Fagioli F., Sessarego M., Gualandi F., van Lint M., Lamparelli T., Occhini D., Figari O., Valbonesi M., Bacigalupo A. The effect of donor leucocyte infusion inpatients with leukemia following allogeneic bone marrow transplantation. Exp. Hematol. 1992; 20: 712
   Web of Science ®Google Scholar
• Porter D., Roth M., McGarigle C., Ferrara J., Antin J. Induction of graft-vs-leukemia (GVL) reaction as therapy for relapsed leukemia after allogeneic bone marrow transplantation (BMT). J. Cell. Biochem. 1994; 18B: 94
   Google Scholar
• Ozer H., George S., Schiffer C., Rao K., Rao N., Wurster-Hill D., Arthur D., Powell B., Gottlieb A., Peterson B., Rai K., Testa J., Le Beau M., Tantravahi R., Bloomfield C. Prolonged subcutaneous administration of recombinant a2b Interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 1993; 82: 2975
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H., Kurzrock R., Trujillo J., Gutterman J. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients. Ann. Intern. Med. 1991; 114: 532
   PubMed Web of Science ®Google Scholar
• Higano C., Raskind W., Flowers M. Alpha Interferon (IFN) results in high complete cytogenetic response rate in patients with cytogenetic-only relapse of chronic myelogenous leukemia CML) after marrow transplantation (BMT). Blood 1993; 82(suppl)661
   Google Scholar
• Higano C., Raskind W., Singer J. Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood 1992; 80: 1437
   PubMed Web of Science ®Google Scholar
• Opalka B., Wandl U., Becher R., Kloke O., Nagel-Hiemke M., Moritz T., Beer U., Seeber S., Niederle N. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon α-2b alone or in combination with Interferon-gamma. Blood 1991; 78: 2188
   PubMed Web of Science ®Google Scholar
• Giralt S., Escudier S., Kantarjian H., Deisseroth A., Freireich E., Anderson B., O'Brien S., Andreeff M., Fisher H., Cork A., et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N. Engl. J. Med. 1993; 329: 757
   PubMed Web of Science ®Google Scholar
• Slavin S., Ackerstein A., Weiss L., Nagler A., Or R., Naparstek E. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest. 1992; 10: 221
   PubMed Web of Science ®Google Scholar
• Slavin S., Naparstek E., Nagler A., Ackerstein A., Drakos P., Kapelushnik Y., Brautbar C., Or R. Cell mediated immunotherapy (CMI) for the treatment of malignant hematological diseases in conjunction with autologous bone marrow transplantation (ABMT). Blood (suppl) 1993; 82a: 1152
   Google Scholar